Abstract:
The present invention provides methods for inhibiting or blocking TGF-β activity in cells and/or tissues expressing TGF-β comprising, contacting cells and/or tissues expressing TGF-β with an amount of cholesterol or cholesterol derivative effective to inhibit the activity of TGF-β. The present invention further provides a method for treating a condition associated with overactivity of TGF-β or negative regulation in normal physiology by TGF-β in a subject in need of treatment, comprising contacting cells and/or tissue overexpressing TGF-β in the subject with an amount of cholesterol or cholesterol derivative effective to inhibit activity of TGF-β thereby treating the condition. In a preferred embodiment, the cholesterol derivative is oxidized 7-DHC.
Abstract:
Microfluidic biofuel cells comprising a bioanode and/or a biocathode are formed using microfluidic principles and soft lithography. The enzymes utilized in the redox reactions at the bioanode and/or the biocathode are stabilized in a micellar or inverted micellar structure. The biofuel cell is used to produce high power densities.
Abstract:
This is a system for determining a position of a probe (302) relative to an object such as a head of a body of a patient. The head includes a surface such as a forehead having a contour. Cross-sectional images of the head are scanned and stored as a function of the forehead contour. If the forehead contour does not appear in the scan images, then the position of the forehead contour relative to the scan images is determined with an optical scanner (380) and ring (590). During surgery, the optical scanner (380) also determines the position of the tip of the forehead relative to the ring (590). An array (300) for receiving radiation emitted from the probe and from the ring generates signals indicating the position of the tip (301) of the probe (302) relative to the ring (590). A stereo-tactic imaging system (324) generates and displays an image of the head corresponding to the measured position of the tip (301) of the probe (302).
Abstract:
The invention is a device (300; 350; 400; 500) for use with a surgical navigation system having a sensor array (110; 112) which is in communication with the device (300; 350; 400; 500) to identify its position. The device (300; 350; 400; 500) is for guiding an instrument for engaging a body part thereby locating the instrument at a known position relative to the body part. It has a connector (340; 370; 408; 514) for engaging a cable connected to the surgical navigation system, the cable for providing signals for activating the device (300; 350; 400; 500). The device (300; 350; 400; 500) comprises:
a housing (308, 310) having a cavity (312; 514) therein; a structure (304; 354; 404; 508) on the housing (308, 310) for guiding the instrument in order to maintain the instrument in a relationship relative to the housing (308, 310); a plurality of light emitting diodes (316; 510) on the housing (308, 310), said diodes (316; 510), when activated, emitting light for communicating with the sensor array (110; 112) of the surgical navigation system; a connector (340; 370; 408; 514) attached to the housing (308, 310) and adapted to engage the cable connected to the surgical navigation system, said connector (340; 370; 408; 514) for receiving the signals for activating the diodes (316; 510); and wires (314; 410; 516) located in the cavity (312; 514) of the housing (308, 310) and electrically interconnecting the connector (340; 370; 408; 514) and the light emitting diodes (316; 510) and for transmitting the signals received by the connector (340; 370; 408; 514) to the diodes (316; 510) to activate the diodes (316; 510).
Abstract:
The present invention is based upon correlation of two attenuating lesions of the cp45 strain to specific defects in the genome of cp45. Specifically, a significant level of attenuation of cp45, resulting from its temperature-sensitive and cold-adapted phenotypes is associated with mutation of the L gene of cp45. A second mutation in the gene coding for hemagglutinin-neuraminidase (HN) in the cp45 strain has also been found to be another attenuating mutation. The correlation of these two attenuating lesions of cp45 to specific genes enables several practical applications. It is now possible to create attenuated vaccines directed at other wild-type HPIV-3 viruses and other viruses other than HPIV-3 by incorporating the mutated L and/or HN genes of cp45 in to a target virus genome or alternatively, expressing surface antigen genes from other viruses in cp45.
Abstract:
A surgical distractor for distracting tissue of a patient to access structure underlying the tissue of the patient. The distractor includes a tube having a distal end adapted for insertion in tissue, a proximal end opposite the distal end, an exterior surface adapted for contacting the tissue, and an interior surface opposite the exterior surface defining a hollow interior extending between the distal end and the proximal end for accessing structure underlying the tissue when the distal end is inserted in the tissue. The distractor is adjustable from a reduced configuration, in which the tube has a reduced width sized for inserting the distal end in the tissue, and an expanded configuration, in which the tube has an expanded width greater than the reduced width sized to provide the hollow interior with a size sufficient for accessing the structure underlying the tissue.
Abstract:
Disclosed are bioanodes comprising a quaternary ammonium treated Nation(R) polymer membrane and a dehydrogenase incorporated within the treated Nation(R) polymer. The dehydrogenase catalyzes the oxidation of an organic fuel and reduces an adenine dinucleotide. The ion conducting polymer membrane lies juxtaposed to a polymethylene green redox polymer membrane, which serves to electro-oxidize the reduced adenine dinucleotide. The bioanode is used in a fuel cell to produce high power densities.